, Tracking Stock Market Picks
Enter Symbol:
Durect Corporation (DRRX) [hlAlert]

down 63.73 %

Durect Corporation (DRRX) rated Buy

Posted on: Thursday,  Sep 20, 2007  9:25 AM ET by Broadpoint Capital

Broadpoint Capital rated Buy Durect Corporation (NASDAQ: DRRX) on 09/20/2007, when the stock price was $5.57. Since
then, Durect Corporation has lost 63.73% as of 01/26/2016's recent price of $2.02.
If you would have followed this Broadpoint Capital's recommendation on DRRX, you would have lost 63.73% of your investment in 3050 days.

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.

Broadpoint Capital, Inc. is an investment banking and capital markets firm that provides corporate and public finance services and trading of corporate, government, and municipal securities for institutions. The company has three divisions: Municipal Capital Markets division, which underwrites and trades municipal securities in new issue and secondary markets; Taxable Fixed Income division, which is a dealer focusing on fixed income securities with limited liquidity; and Equity Capital Markets division, which is a sector-focused investment banking group providing research, trading, raising of capital and advisory services for institutional and corporate clients. Broadpoint Capital, formerly known as First Albany Corporation, was founded in 1953 and is based in New York, New York. The company operates as a subsidiary of First Albany Companies Inc.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/20/2007 9:25 AM Buy
5.57 10.25
as of 8/27/2015
1 Week down  -2.88 %
1 Month down  -18.87 %
3 Months down  -13.67 %
1 YTD up  16.76 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy